Effect of anti-inflammatory drug therapy on clearance of 133-Xe from knee joints of patients with rheumatoid arthritis. 1969

C Dick, and P H Dick, and G Nuki, and K Whaley, and J A Boyle, and A Shenkin, and W W Downie, and W W Buchanan

The degree of joint inflammation in 13 patients with rheumatoid arthritis, as measured by clinical indices, was reduced by both sodium salicylate and indomethacin. The clearance rate of (133)Xe was reduced by indomethacin alone, and showed no correlation with the clinical features.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007270 Injections, Intra-Articular Methods of delivering drugs into a joint space. Intra Articular Injection,Intraarticular Injection,Injections, Intraarticular,Intra-Articular Injections,Intraarticular Injections,Articular Injection, Intra,Articular Injections, Intra,Injection, Intra Articular,Injection, Intra-Articular,Injection, Intraarticular,Injections, Intra Articular,Intra Articular Injections,Intra-Articular Injection
D007717 Knee A region of the lower extremity immediately surrounding and including the KNEE JOINT.
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011868 Radioisotopes Isotopes that exhibit radioactivity and undergo radioactive decay. (From Grant & Hackh's Chemical Dictionary, 5th ed & McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Daughter Isotope,Daughter Nuclide,Radioactive Isotope,Radioactive Isotopes,Radiogenic Isotope,Radioisotope,Radionuclide,Radionuclides,Daughter Nuclides,Daugter Isotopes,Radiogenic Isotopes,Isotope, Daughter,Isotope, Radioactive,Isotope, Radiogenic,Isotopes, Daugter,Isotopes, Radioactive,Isotopes, Radiogenic,Nuclide, Daughter,Nuclides, Daughter
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D012980 Sodium Salicylate A non-steroidal anti-inflammatory agent that is less effective than equal doses of ASPIRIN in relieving pain and reducing fever. However, individuals who are hypersensitive to ASPIRIN may tolerate sodium salicylate. In general, this salicylate produces the same adverse reactions as ASPIRIN, but there is less occult gastrointestinal bleeding. (From AMA Drug Evaluations Annual, 1992, p120) Salicylate, Sodium

Related Publications

C Dick, and P H Dick, and G Nuki, and K Whaley, and J A Boyle, and A Shenkin, and W W Downie, and W W Buchanan
December 1972, Fysiatricky a reumatologicky vestnik,
C Dick, and P H Dick, and G Nuki, and K Whaley, and J A Boyle, and A Shenkin, and W W Downie, and W W Buchanan
April 1970, Acta rheumatologica Scandinavica,
C Dick, and P H Dick, and G Nuki, and K Whaley, and J A Boyle, and A Shenkin, and W W Downie, and W W Buchanan
January 1967, Scandinavian journal of clinical and laboratory investigation. Supplementum,
C Dick, and P H Dick, and G Nuki, and K Whaley, and J A Boyle, and A Shenkin, and W W Downie, and W W Buchanan
January 1987, Scandinavian journal of rheumatology,
C Dick, and P H Dick, and G Nuki, and K Whaley, and J A Boyle, and A Shenkin, and W W Downie, and W W Buchanan
January 1981, Scandinavian journal of gastroenterology. Supplement,
C Dick, and P H Dick, and G Nuki, and K Whaley, and J A Boyle, and A Shenkin, and W W Downie, and W W Buchanan
April 1987, British journal of rheumatology,
C Dick, and P H Dick, and G Nuki, and K Whaley, and J A Boyle, and A Shenkin, and W W Downie, and W W Buchanan
October 2008, Reumatologia clinica,
C Dick, and P H Dick, and G Nuki, and K Whaley, and J A Boyle, and A Shenkin, and W W Downie, and W W Buchanan
February 2023, Rheumatology international,
C Dick, and P H Dick, and G Nuki, and K Whaley, and J A Boyle, and A Shenkin, and W W Downie, and W W Buchanan
June 2017, International journal of rheumatic diseases,
C Dick, and P H Dick, and G Nuki, and K Whaley, and J A Boyle, and A Shenkin, and W W Downie, and W W Buchanan
June 1958, Annals of the rheumatic diseases,
Copied contents to your clipboard!